News | April 01, 2014

Frost & Sullivan Recognizes Sensus for Development of Low-Energy Radiotherapy Systems for Skin Cancer

Products have demonstrated safety, clinical efficacy and potential for widespread adoption to treat dermatological and oncological conditions, says analyst

April 1, 2014 — Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognized Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two low-energy X-ray devices, SRT-100 and SRT-100 Vision.

Competing products use electron beams ranging from 1 to 12 mega electron volts (MeV), or decaying isotope-based emitting sources. Patients are typically subjected to radiation levels many times the energy required for non-melanoma skin cancer treatment, with only a part of the energy being delivered to the surface of the skin. The SRT-100 and SRT-100 Vision use kilovoltage X-rays in the 50 to 100 kilo volts (KV) energy range. The radiation is delivered completely to the surface of the skin, without affecting the underlying healthy tissue and cells. SRT is ideal for irradiating tumorous growths at depths of between 0.5 mm and 5 mm.

The systems are small footprint and portable devices, similar in size and design to an ultrasound instrument. The SRT-100 Vision integrates high-resolution ultrasound imaging and laser positioning capabilities to help with the accurate localization, characterization and topology of lesions. This, in turn, will ensure optimal energy dosage, treatment fractionation and depth of beam penetration.

"SRT-100 and SRT-100 Vision utilize a noninvasive approach that does not leave scars and therefore eliminates the need for additional follow-up procedures, such as skin grafting and cosmetic reconstructive surgeries," said Frost & Sullivan Research Analyst Bhargav Rajan. "There is no loss of skin and/or sensation, and since it is a non-contact procedure, it is painless. The entire procedure lasts only seconds for each treatment fraction, compared to surgeries and other procedures, which take hours and additional recovery time."

A retrospective assessment of more than 1,700 patients who were treated for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) using SRT-100 showed a 98 percent cure rate over two years, and a more than 95 percent cure rate over five years. These remarkable cure rates are comparable with those obtained using current clinical standards.

"SRT-100 has come to be considered medically necessary and/or an adjunctive procedure for the treatment of non-melanoma skin cancers and non-oncological skin conditions such as keloids," said Rajan. "Due to its record for safety, efficacy and low risks, it is covered by most insurance companies and Medicare for oncological and non-oncological procedures."

The U.S. Food and Drug Administration (FDA) recently granted 510(k) clearance to the SRT-100 for treating keloids (collagen-based non-malignant scars). With this regulatory approval, SRT-100 and SRT-100 Vision can now be used to treat non-oncological conditions (keloids) and pre-oncological conditions such as actinic keratosis.

For more information: www.frost.com

Related Content

Sponsored Content | Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Synthetic CT Images Suitable for Prostate Cancer Radiotherapy Planning
News | Treatment Planning | November 14, 2017
Spectronic Medical announced that new data for their MRIPlanner software, generating synthetic computed tomography (sCT...
ASTRO: CMS Report on Radiation Therapy Payment Model Charts Path to Value-Based Cancer Care
News | Radiation Therapy | November 08, 2017
The American Society for Radiation Oncology (ASTRO) called on the Centers for Medicare and Medicaid Services (CMS) to...
U.S. Recognizes Radiologic Technologists Nov. 5-11
News | Imaging | November 06, 2017
November 6, 2017 — During National Radiologic Technology Week (NRTW) every November, hospitals, healthcare centers an
Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust
News | Radiation Therapy | November 06, 2017
November 6, 2017 — Nearly one-third of women with...
PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy
News | Proton Therapy | November 01, 2017
Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy...
Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients
News | Proton Therapy | November 01, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional...
Cleveland Clinic Leads Development of New Guidelines for Radiation in Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 31, 2017
October 31, 2017 — Cleveland Clinic researcher Chirag Shah, M.D., recently led the development of updated guidelines
Proton Therapy Shows Promising Clinical Benefits for Esophageal, Prostate and Breast Cancer
News | Proton Therapy | October 30, 2017
The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing promising results were...
UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System
News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017
Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be...
Overlay Init